• Je něco špatně v tomto záznamu ?

Detection of tumor antigens and tumor-antigen specific T cells in NSCLC patients: Correlation of the quality of T cell responses with NSCLC subtype

O. Palata, N. Podzimkova Hradilova, D. Mysiková, B. Kutna, H. Mrazkova, R. Lischke, R. Spisek, I. Adkins,

. 2020 ; 219 (-) : 46-53. [pub] 20200110

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028444

Allogeneic cancer cell lines serve as universal source of tumor-associated antigens in cancer vaccines. Immunogenic high hydrostatic pressure-killed cancer cells derived from cell lines can be used for the generation of dendritic cell (DC)-based active cellular immunotherapy of non-small cell lung cancer (NSCLC). We investigated the expression of 12 known NSCLC tumor-associated antigens (TAA) (CEA, MAGE-A1, MAGE-A3, MAGE-A4, PRAME, hTERT, HER2, MUC1, Survivin, STEAP1, SOX2 and NY-ESO-1) in 6 NSCLC cell lines as candidates for the generation of DC-based lung cancer vaccine. We showed that the selected antigenic profile of these cell lines overlaps to various degrees with that of primary NSCLC tumors (n = 52), indicating that 4 out of 6 NSCLC cell lines would be suitable for DC-based vaccine generation. We further investigated the presence of TAA-specific T cells in blood of NSCLC patients (n = 32) using commercially available peptide mixes in an in vitro stimulation assay. IFN-γ+CD8+ and IFN-γ+CD4+ T cell responses to all antigens were detected in NSCLC patients. Interestingly, despite higher TAA expression in squamous cell carcinoma (SCC) the responsiveness of patients' T cells to stimulation was significantly lower in SCC patients than in adenocarcinoma (AC) patients. This suggests qualitative differences in T cell functionality between NSCLC subtypes. Based on this study, and in order to maximize the amount of treatable patients, we selected a mix of H520 and H522 NSCLC cell lines for DC-based vaccine preparation. We also established a minimal panel of antigenic peptide mixes (CEA, hTERT, PRAME, HER2) for immunomonitoring of T cell responses during the DC-based lung cancer immunotherapy in Phase I lung cancer clinical trial (NCT02470468).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028444
003      
CZ-PrNML
005      
20210114153901.0
007      
ta
008      
210105s2020 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.imlet.2020.01.001 $2 doi
035    __
$a (PubMed)31931024
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Palata, Ondrej $u Sotio, Prague, Czech Republic; Department of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Czech Republic.
245    10
$a Detection of tumor antigens and tumor-antigen specific T cells in NSCLC patients: Correlation of the quality of T cell responses with NSCLC subtype / $c O. Palata, N. Podzimkova Hradilova, D. Mysiková, B. Kutna, H. Mrazkova, R. Lischke, R. Spisek, I. Adkins,
520    9_
$a Allogeneic cancer cell lines serve as universal source of tumor-associated antigens in cancer vaccines. Immunogenic high hydrostatic pressure-killed cancer cells derived from cell lines can be used for the generation of dendritic cell (DC)-based active cellular immunotherapy of non-small cell lung cancer (NSCLC). We investigated the expression of 12 known NSCLC tumor-associated antigens (TAA) (CEA, MAGE-A1, MAGE-A3, MAGE-A4, PRAME, hTERT, HER2, MUC1, Survivin, STEAP1, SOX2 and NY-ESO-1) in 6 NSCLC cell lines as candidates for the generation of DC-based lung cancer vaccine. We showed that the selected antigenic profile of these cell lines overlaps to various degrees with that of primary NSCLC tumors (n = 52), indicating that 4 out of 6 NSCLC cell lines would be suitable for DC-based vaccine generation. We further investigated the presence of TAA-specific T cells in blood of NSCLC patients (n = 32) using commercially available peptide mixes in an in vitro stimulation assay. IFN-γ+CD8+ and IFN-γ+CD4+ T cell responses to all antigens were detected in NSCLC patients. Interestingly, despite higher TAA expression in squamous cell carcinoma (SCC) the responsiveness of patients' T cells to stimulation was significantly lower in SCC patients than in adenocarcinoma (AC) patients. This suggests qualitative differences in T cell functionality between NSCLC subtypes. Based on this study, and in order to maximize the amount of treatable patients, we selected a mix of H520 and H522 NSCLC cell lines for DC-based vaccine preparation. We also established a minimal panel of antigenic peptide mixes (CEA, hTERT, PRAME, HER2) for immunomonitoring of T cell responses during the DC-based lung cancer immunotherapy in Phase I lung cancer clinical trial (NCT02470468).
650    _2
$a senioři $7 D000368
650    _2
$a antigeny nádorové $x imunologie $7 D000951
650    _2
$a protinádorové vakcíny $7 D019496
650    _2
$a nemalobuněčný karcinom plic $x imunologie $x metabolismus $x patologie $x terapie $7 D002289
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a dendritické buňky $x imunologie $x metabolismus $7 D003713
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunoterapie $7 D007167
650    _2
$a nádory plic $x imunologie $x metabolismus $x patologie $x terapie $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    12
$a antigenní specifita receptorů T-buněk $7 D037182
650    _2
$a T-lymfocyty $x imunologie $x metabolismus $7 D013601
650    _2
$a cytotoxické T-lymfocyty $x imunologie $x metabolismus $7 D013602
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Podzimkova Hradilova, Nada $u Sotio, Prague, Czech Republic; Department of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Czech Republic.
700    1_
$a Mysiková, Dagmar $u Thoracic and Lung Transplantation Division, 3rd Department of Surgery, First Faculty of Medicine, Charles University in Prague and University Hospital Motol, Czech Republic.
700    1_
$a Kutna, Beata $u Thoracic and Lung Transplantation Division, 3rd Department of Surgery, First Faculty of Medicine, Charles University in Prague and University Hospital Motol, Czech Republic.
700    1_
$a Mrazkova, Hana $u Thoracic and Lung Transplantation Division, 3rd Department of Surgery, First Faculty of Medicine, Charles University in Prague and University Hospital Motol, Czech Republic.
700    1_
$a Lischke, Robert $u Thoracic and Lung Transplantation Division, 3rd Department of Surgery, First Faculty of Medicine, Charles University in Prague and University Hospital Motol, Czech Republic.
700    1_
$a Spisek, Radek $u Sotio, Prague, Czech Republic; Department of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Czech Republic.
700    1_
$a Adkins, Irena $u Sotio, Prague, Czech Republic; Department of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Czech Republic. Electronic address: adkins@sotio.com.
773    0_
$w MED00002200 $t Immunology letters $x 1879-0542 $g Roč. 219, č. - (2020), s. 46-53
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31931024 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114153858 $b ABA008
999    __
$a ok $b bmc $g 1608779 $s 1119624
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 219 $c - $d 46-53 $e 20200110 $i 1879-0542 $m Immunology letters $n Immunol Lett $x MED00002200
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace